Novel therapeutic intervention for osteoporosis prepared with strontium hydroxyapatite and zoledronic acid: In vitro and pharmacodynamic evaluation

Keyphrases

• Acid Groups 10%
• Anti-osteoporosis Drugs 5%
• Bisphosphonates 10%
• Bone Alkaline Phosphatase 5%
• Bone Formation 5%
• Bone Properties 5%
• Bone Specimen 5%
• Calcium Phosphate Ratio 10%
• Direct Delivery 5%
• Drug Formulation 15%
• Energy Dispersive X-ray Analysis 5%
• Experimental Osteoporosis 5%
• Field Emission Scanning Electron Microscopy (FE-SEM) 5%
• Fourier Transform Infrared Spectroscopy (FT-IR) 5%
• Hydroxyapatite Nanoparticles 10%
• In Vitro Evaluation 100%
• Intravenous Dose 5%
• Mechanical Strength 5%
• Monotherapy 5%
• Nanoparticles 15%
• Novel Therapeutics 100%
• Osteoporosis 100%
• Ovariectomized Rat Model 5%
• Ovariectomy Rat 5%
• Pharmacodynamic Evaluation 100%
• Postmenopausal Osteoporosis 5%
• Published Data 5%
• Strontium 5%
• Strontium Hydroxyapatite 100%
• Targeted Delivery 5%
• Tartrate-resistant Acid Phosphatase 5%
• Therapeutic Intervention 100%
• Trabecular Microarchitecture 5%
• X Ray Diffraction 5%
• Zoledronic Acid 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Acid Phosphatase Tartrate Resistant Isoenzyme 5%
• Alkaline Phosphatase 5%
• Bisphosphonic Acid Derivative 10%
• Drug 5%
• Drug Formulation 15%
• Experimental Osteoporosis 5%
• Field Emission Scanning Electron Microscopy 5%
• Fourier Transform Infrared Spectroscopy 5%
• Hydroxyapatite 100%
• Monotherapy 5%
• Nanoparticle 26%
• Pharmacodynamics 100%
• Postmenopause Osteoporosis 5%
• Rat Model 5%
• Zoledronic Acid 100%